Literature DB >> 8353407

PHLECO: a multicenter study of the fate of 1647 hospital patients treated conservatively without fibrinolysis and surgery.

M Martin1.   

Abstract

The PHLECO Study (phlebothrombosis conservative therapy) is a multicenter investigation of patients with deep vein thrombosis receiving conservative nonfibrinolytic hospital treatment. A second study (part II: PHLEFI, phlebothrombosis fibrinolytic treatment) to be published later deals with the outcome of fibrinolytic therapy. In both studies the incidence of life-threatening sequelae, such as pulmonary embolism, is of major interest. The 49 medical departments participating in the study mailed the relevant data to the Duisburg Coordination Center for further data analysis and the following information was gained: (a) In descending order of frequency, the clinical conditions of thrombosis were: immobility, postoperative status, malignancy, hormone treatment, posttraumatic conditions, and pregnancy. (b) In descending order of frequency, the sites of thrombosis were: femoral vein, calf vein, iliac vein, popliteal vein, and subclavian vein. Left-sided thrombosis predominated in the iliac and subclavian vein groups. (c) In descending order of frequency, the treatment regimens employed were: intravenous heparin+oral anticoagulants, intravenous heparin+subcutaneous heparin, intravenous heparin alone, subcutaneous heparin alone, intravenous heparin+subcutaneous heparin+oral anticoagulants, subcutaneous heparin+oral anticoagulants, intravenous heparin+platelet aggregation inhibitors. (d) The average hospital stay was 23.7 +/- 15.6 days. No correlation existed between duration of hospital stay and particular types of therapy. (e) The incidence of nonfatal pulmonary embolism was 16.1% while that of fatal pulmonary embolism was 2.33%. (f) Women outnumbered men in the group with fatal pulmonary embolism, and the death rate among older patients was higher than that among younger patients. (g) Patients with fatal pulmonary embolism had a shorter history of thrombosis than patients in the unselected cohort (patients with and without pulmonary embolism).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353407     DOI: 10.1007/bf00180062

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  25 in total

1.  [Fatal lung embolism during ultrahigh-dose streptokinase treatment].

Authors: 
Journal:  Dtsch Med Wochenschr       Date:  1990-11-23       Impact factor: 0.628

Review 2.  [Heparin or thrombolysis in the treatment of deep venous thrombosis of the leg].

Authors:  L K Widmer; G Madar; H E Schmitt; F Duckert; M A da Silva; G Müller
Journal:  Vasa       Date:  1974       Impact factor: 1.961

3.  Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. A comparative study between streptokinase and heparin therapy.

Authors:  R Watz; G F Savidge
Journal:  Acta Med Scand       Date:  1979

4.  Assessment of anticoagulant treatment of venous thromboembolism.

Authors:  W W Coon; P W Willis; M J Symons
Journal:  Ann Surg       Date:  1969-10       Impact factor: 12.969

5.  [Epidemiology of venous thromboembolism].

Authors:  L Biland; E Zemp; L K Widmer
Journal:  Internist (Berl)       Date:  1987-05       Impact factor: 0.743

6.  [Physiologic studies of blood coagulation in deep venous thrombosis].

Authors:  H K Breddin; V Hach-Wunderle
Journal:  Internist (Berl)       Date:  1987-05       Impact factor: 0.743

7.  Massive fatal pulmonary emboli with fibrinolytic therapy.

Authors:  J C Goldsmith; P Lollar; J C Hoak
Journal:  Circulation       Date:  1981-11       Impact factor: 29.690

Review 8.  Epidemiology of venous thromboembolism.

Authors:  W W Coon
Journal:  Ann Surg       Date:  1977-08       Impact factor: 12.969

9.  Free-floating iliofemoral thrombus. A risk of pulmonary embolism.

Authors:  C S Norris; L J Greenfield; J B Herrmann
Journal:  Arch Surg       Date:  1985-07

10.  [Ultra-high dose thrombolytic therapy with streptokinase in peripheral venous thrombosis].

Authors:  H Fahn; P Maubach; R Merkl; H Senner; H Hellwig; A Wirtzfeld
Journal:  Med Klin (Munich)       Date:  1989-04-15
View more
  1 in total

1.  [Vena cava filter].

Authors:  T Helmberger
Journal:  Radiologe       Date:  2007-05       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.